Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06, FiscalAI reports. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The firm had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million.
Here are the key takeaways from Autolus Therapeutics’ conference call:
- AUCATZYL net product revenue rose to $45.7 million in Q2 2026, up from $26.2 million in Q1 and $20.9 million a year earlier. Management raised full-year 2026 revenue guidance to $140 million–$150 million.
- Commercial expansion is progressing faster than planned, with more than 80 U.S. authorized treatment centers already active by midyear and approximately 20 U.K. centers expected by year-end. Management said most activated centers have already treated patients and reported strong physician adoption.
- Gross margin improved sharply to 55% from 6% in Q1, driven by higher manufacturing volumes, production at the U.K. Nucleus facility, operating efficiencies, and cost reductions. The company is targeting a 65%–70% gross margin for the mature adult ALL business within roughly 12–18 months.
- Management outlined multiple upcoming clinical catalysts, including longer-term CARLYSLE lupus data and initial AUTO8 amyloidosis data by year-end 2026, BOBCAT progressive multiple sclerosis data in 2027, and potential pediatric ALL and lupus nephritis milestones in 2027–2028.
- Autolus drew an initial $75 million under a Perceptive Advisors credit facility, with up to $250 million potentially available subject to revenue milestones. Combined with cash, marketable securities, and anticipated revenue, management expects runway into Q2 2028, though the financing increases future debt obligations.
Autolus Therapeutics Stock Performance
Shares of NASDAQ:AUTL traded up $0.18 during midday trading on Tuesday, hitting $2.25. The company’s stock had a trading volume of 1,289,334 shares, compared to its average volume of 1,687,173. The business’s 50 day simple moving average is $1.59 and its 200 day simple moving average is $1.55. The company has a market cap of $600.19 million, a P/E ratio of -2.12 and a beta of 2.07. Autolus Therapeutics has a 12-month low of $1.17 and a 12-month high of $2.50.
Institutional Trading of Autolus Therapeutics
Analyst Upgrades and Downgrades
AUTL has been the topic of several analyst reports. Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Finally, Wall Street Zen upgraded Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.75.
View Our Latest Stock Analysis on AUTL
About Autolus Therapeutics
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Featured Articles
- Five stocks we like better than Autolus Therapeutics
- Meta’s Muse Glimmer Release Reframes Its AI Spending Bet
- 3 Companies That Could Thrive While the Fed Holds Rates Steady
- Caterpillar’s Blowout Quarter May Point to More Industrial Winners
- Jeff Bezos’ Amazon Sale Looks Less Alarming Than the Headline Suggests
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
